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are still within the framework defined for this technol-
ogy. CONCLUSION: Setting clear guidelines is essential
for regulating drug consumption. 
MULTIPLE DISORDERS—PATIENT PREFERENCE
PMDP1
WILLINGNESS TO PAY FOR AVOIDING 
ADVERSE EFFECTS OF DRUGS
Rodríguez R, Rovira J
Grup de Recerca en Economia de la Salut i Seguretat Social, 
Universitat de Barcelona, Barcelona, Spain
OBJECTIVE: To obtain monetary valuations of the dis-
utility associated with mild and moderate adverse effects
(AE) of drug treatments for reumathoidic arthritis (RA).
METHODS: Four frequent AE for the treatments of RA
(rush, mild gastrointestinal disorders, vomiting and head-
ache) were defined with the help of a focus group with
RA patients. Later, 175 individuals randomly selected
from a Spanish community were personally surveyed with
the help of a questionnaire. Respondents were first asked
to rank the AE by order of disutility. Then, the WTP for
a reduction of the probability of each AE (by 100, 80 and
50 per cent), as well as for avoiding the symptoms of RA
was assessed. The disutility of the AE in relation to the
symptoms of RA was assessed by means of the standard
gamble approach. The consistency of the results was
tested by comparing the direct rankings with those de-
rived from the WTP and standard gamble exercises. RE-
SULTS: The average WTP for avoiding the AE in thou-
sand PTA. per year was: rush, 24.6; vomiting, 43.3;
headache, 45.7; and gastrointestinal disorders, 63.1.
Consistency was very high in the WTP, 96.8% and
79.1% in the case of the standard gamble. In the case of
rush, the WTP for different risks reductions (100, 80 and
50%) the consistency was 98.26%, 90.17% and 79.19%
respectively. CONCLUSION: the avoidance of AE is be-
coming an increasingly important feature of innovative
treatments. Generic utility measures of health are often
not sensitive enough to adequately quantify the disutility
of mild AE. WTP seems to provide a valid alternative,
which shows a higher degree of consistency than the of-
ten recommended standard gamble approach.
PMDP2
CONSUMER USE OF THE INTERNET FOR 
HEALTHCARE INFORMATION
Donohue JA
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To describe people who use the internet for
healthcare information and compare them to those who
do not, based on physician visits, health status, and health-
care attitudes. METHODS: Analyses were based on a 12-
page questionnaire mailed to US adults in 1999. A total
of 19,863 (54.9%) responses were received. Respondents
were nationally representative based on age, gender,
race, and geographic region; results were subsequently
weighted and projected to the US population. Partici-
pants were asked how often in the past six months they
received healthcare information from the internet. Re-
sponses were on a five-point scale from “not at all” to
“very frequently” and were subsequently categorized as
not at all (1), occasional (2–3), and frequent (4–5). RE-
SULTS: Three quarters of the sample (149.4 million) re-
ported never using the internet for healthcare informa-
tion, 17% (33.1 million) reported occasional use, and
8% (16.9 million) reported frequent use. Internet users
were more likely to young, female, better educated, and
have higher incomes. Those who used the internet for
healthcare information were more proactive consumers
than non-users. They were more likely to ask doctors for
prescriptions and to question physicians’ advice. These
attitudes and behaviors held true for both frequent and
occasional internet healthcare information seekers, but
were even more extreme for the frequent seekers. CON-
CLUSION: Most American adults did not seek internet
healthcare information. Those who frequency sought such
information, however, were “cyberchondriacs.” When
compared to the general population, they were less satis-
fied with their healthcare, were in poorer health, visited
physicians and alternative health providers more often,
missed more days of work due to poor health, and were
likely to seek healthcare information from a variety of
sources. They did not look like the typical healthcare
consumer. Occasional users, however, were much more
representative of those who typically seek healthcare in-
formation.
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The Health Utilities Index is a generic multiattribute pref-
erence-based system for assessing health-related quality
of life, originally devised by Torrance et al. It is being
widely used in cost-effectiveness evaluations in North
America and in international multicentre studies but was
not available in France. OBJECTIVE: Following cross-
cultural adaptation and validation of the HUI3 classifica-
tion in the French population, the purpose of this investi-
gation was to derive population weights for the French
instrument. METHODS: In June 1999, we implemented
a population (n  365) preference survey. Respondants
were randomly selected by phone to be representative of
the structure French general population and face-to-face
interviews were conducted. Visual Analog Scale (VAS)
and Standard Gamble (SG) were used to reveal prefer-
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ences on a scale running from 1 (perfect health) to 0 (all
worst or death depending on the interviewee’s decision).
The 8 single-attribute value functions were directly re-
vealed as well as the corner states values. Rating of par-
ticular multi-attribute health states was also done using
both VAS and SG. RESULTS: The limited number of
questionnaires excluded at the various different stages of
building the multiattribute utility function demonstrated
that such approaches are viable manners of gathering
original and high-quality information on the values and
judgements held by individuals in France with regard to
health. Secondly, analysis concluded that collected data
permit 1) to fit multi-attribute value and utility functions
for many individuals and 2) to discuss the appropriate-
ness of the multiplicative functional form. Results ob-
tained at the person-mean and person-median levels from
the French survey will be presented and discussed. Our
results confirm the interindividual variability of the pref-
erences already reported among Anglo-Saxon popula-
tions. As for most of the latter, these variations cannot be
explained by standard socio-demographic characteristics
such as the age, sex or socio-economic level of the inter-
viewees.
PMDP4
THE INFLUENCE OF NON-COMPLIANCE ON 
THE EFFECTIVENESS AND COST-
EFFECTIVENESS OF DRUG THERAPIES
Hughes D, Bagust A, Haycox A, Walley T
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OBJECTIVES: To develop a model for predicting thera-
peutic effectiveness from efficacy data. To estimate the
resource and health implications of sub-optimal drug use
in the general population. METHODS: A stochastic model-
ling approach was adopted to simulate drug effect ac-
cording to time. Non-compliance was simulated by prob-
ability functions describing the three main forms of drug-
taking behaviour: timing errors, missed doses and drug
holidays. Standard pharmacokinetic (PK) simulations for
multiple oral dosing based on these dosing profiles pro-
vided a basis for pharmacodynamic (PD) modelling in or-
der to evaluate the time course of drug effect. Iterations
were made for each PK-PD model with random compli-
ance profiles. RESULTS: Although the consequences of
non-compliance are varied, and mainly dependent upon
the disease being treated, some drugs are more forgiving
to non-compliance than others. That is, in the presence of
erratic dosing behaviour, therapeutic effect may be main-
tained. Forgiveness is an attribute which is dependent
both upon the properties of the drug and the pathophysi-
ology of the disease. The model demonstrates that drugs
which have a long duration of action in relation to their
dosing interval are the most forgiving, and this may be pre-
dicted on the basis of their PK-PD characteristics. CON-
CLUSIONS: Non-compliance is an important factor of
drug effectiveness. The forgiveness of a drug determines
the extent to which efficacy is affected by sub-optimal
drug use and has implications when considering cost-
effectiveness.
MULTIPLE DISORDERS—METHODOLOGY ISSUES
PMDM1
POWER AND SAMPLE SIZE CALCULATIONS 
FOR A CLINICAL TRIAL CONSIDERING COST-
EFFECTIVENESS AND STATISTICAL ERRORS
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In the last meeting of ISPOR, we presented a paper that
showed the actual cost-effectiveness of treatments in
practice can be reduced by the influence of statistical er-
rors such as type II () and type III (). OBJECTIVE:
Based on that research, this paper developed a further
theoretical framework for such estimation which pro-
vides a new method for power analysis of a clinical trial
and proper translation of its outcomes in terms of cost-
effectiveness. METHODS: Consider a statistical model of
a clinical trial for two regimens: a new treatment TA and
TB. Under the traditional two-sample binomial analysis,
we theoretically expanded it into power and sample sized
calculations with the cost-effectiveness ratios A and B,
respectively, for the regimens TA and TB. Furthermore, we
assume that the truth is TA is more cost-effective than TB.
Then, the binomial analyses were generalized under the
decision-analytic model that can reflect a reality in prac-
tice with three alternatives according to no error,  and 
errors possibly contained in the statistical conclusion of
the clinical trials for TA and TB. RESULTS: Two formu-
lae were developed mathematically to incorporate cost-
effectiveness; one is an expansion of the traditional
formula for sample-size calculation with the cost-effec-
tiveness ratios A and B, and the other a more realistic
one with A and B, and the modified cost-effectiveness
ratio adjusted by the statistical  and  errors using A
and B. CONCLUSIONS: The newly developed formulae
can offer a more theoretically sound description to design
a clinical trial beyond the traditional techniques.
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OBJECTIVE: Our goal was to develop a set of evidence-
based guiding principles for the comparison of two novel
drugs of the same therapeutic class when direct head-to-
head comparisons are lacking. The principles are in-
tended to guide researchers, decision-makers, and formu-
